A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single‐Dose, Phase 1 Crossover Trial

Atogepant is a selective, oral calcitonin gene–related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double‐blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single supratherapeutic (300 mg) atogepant dose vs placebo i...

Descripción completa

Detalles Bibliográficos
Autores principales: Boinpally, Ramesh, McNamee, Brian, Yao, Li, Butler, Matthew, McGeeney, Danielle, Borbridge, Lisa, Periclou, Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453716/
https://www.ncbi.nlm.nih.gov/pubmed/33942560
http://dx.doi.org/10.1002/cpdd.940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453716/
https://www.ncbi.nlm.nih.gov/pubmed/33942560
http://dx.doi.org/10.1002/cpdd.940

Ejemplares similares